

Introduction to MiDatabank Version 3

MiDatabank Version 3 is a major new release that has many new features. The following is a brief summary that introduces some of these features.

New Features for the Pharmaceutical Industry:

- Recording of Product-related MI Enquiries
- Recording of Product-related Complaints for transfer to QA Department
- Recording of Product-related Adverse Drug Reactions
 - Facility to transfer ADR data to Pharmacovigilance Department
 - Facility to electronically transmit ADR data (e.g. Yellow Card in the UK) to Regulatory Authority

New Features for Hospitals:

- Streamline the recording of enquiries
- Broadening the scope to be a core tool in Hospital Pharmacy
- Enable Clinical Pharmacists to record enquiries
- Supporting Pharmacists with their Professional Development
- Electronically transmit ADR data (e.g. Yellow Card in the UK) to Regulatory Authority

MiDatabank Document Types

MiDatabank can create, edit and manage the following types of document

- Enquiries
 - Medicines Information Enquiries
 - ADR Enquiries
 - Complaints
- FAQs - Frequently Asked Question
- Projects - Documentation of Formulary decisions, Horizon Scanning etc

Medicines Information (MI) Enquiries

MiDatabank has an established mechanism to record a MI type of enquiry. This involves documenting the process of taking data input, performing research and transfer of the answer to the enquirer.

With version 3 of MiDatabank, there are a number of new facilities:

Helper Panel - a panel on the left-hand side that can be shown by clicking on the 'Further Information' below, click on the 'Research' tab above

Once you have collected the Further Information below, click on the 'Research' tab above

Interactions

Clinical Guide: www.midatabank.com/clinicalguides/interactions.pdf

Further Information Required:

When documenting your case describe:

After the patient is fully taking both medicines:

If they are already being taken, is there any sign of patient harm?

The other medicines the patient is taking.

Help Needed from MI No

Show Helper Status: In Tray

Facility for new users to request assistance from more experienced MI staff

Atorvastatin And Erythromycin - Clinical Significance Of The Interaction?

Recorded Time: 18/02/2011 00:13:59

Enquirer: Surname: Butler, First Name: Caroline, Name: Caroline Butler, Job: Hospital Pharmacy Staff, Status: Hospital Pharmacy Staff, Dept: 0117 7345 34, Tel: Blp, Email: More>

Contact for this Enquiry: k7362, Blp 232, Route: Telephone

Due By: 11:16 on 18 February 2010

Attachment: Add... Remove

Question: A Verdana 10 B I U

Atorvastatin and erythromycin - what is the significance of the interaction? BNF says to avoid concomitant use.

Title: Atorvastatin And Erythromycin - Clinical Significance Of The Interaction? Auto Title

Medication: 3 Items Add...

- Atenolol 50mg tablets:** Dosage: Route: Oral, Start: 01/01/2010, Exp: (none), Presc for:
- Glyceryl trinitrate 300mcg sublingual tablets:** Dosage: Route: Start: (none), Exp: (none), Presc for:
- Atorvastatin 20mg tablets:** Dosage: Route: Start: (none), Exp: Presc for:

Keywords: Add Remove, Auto Keyword, ERYTHROMYCIN, ATORVASTATIN, Allocate to Me

The National Drugs Dictionary DM+D is available to choose the Patient's Medication

Centres can add their own categories if required

Research Types:

- Past Enquiries
- FAQs
- Resources

Automatic Search of Past Enquiries and FAQs using Category and Keywords

Atorvastatin And Erythromycin - Clinical Significance Of The Interaction?

Recorded Time: 31/01/2011 00:13:43

Search: Recommended Sources All Sources Add Research

Search For: Past Enquiries FAQs Include Invalid FAQs Show Quick View

3 Hits

- Atorvastatin FAQ
- Garlic - any interaction with enalapril or aspirin?
- Is there an interaction between amiodarone and...

Categories: Interactions

AND Keywords: ATORVASTATIN ERYTHROMYCIN

OR ATORVASTATIN ERYTHROMYCIN

Search Again

Selected Item: Past Enquiry: Garlic - any interaction with enalapril or aspirin? Show Enquiry


Show Helper Status: In Progress Enq No: 217 Taken By: DW on 25/01/2010 05:35:00 Allocated to: SS Allocate to Me

Quick View facility to enable rapid perusal of the selected Past Enquiry or FAQ


Standard Search Pattern (SSP) that displays the recommended sources for the enquiry category.

This is a ranked list of sources that should be consulted when doing research.

The SSP can be configured by individual centres as required




Extended Word Processing facilities for documenting the Answer



Selection of Template (ie Header and Footer) for the document


Special Fields can be inserted into the Answer. These include the Enquirer postal address, Patient Details, User's signature and pre-defined Standard Paragraphs or Standard Responses

Continuing Professional Development:
Users can add their competencies to an enquiry.




The new facilities are configurable in the MiDatabank Administration module. For example, the screen-shot show below shows an additional category 'Possible Q & A' has been added to the standard set of categories.

In addition, note that there are 'Over-ride' buttons that enable the text displayed in the Helper Panel, and the Standard Search Pattern to be customised according to needs of the centre.



Adverse Drug Reactions (ADR) Enquiries

MiDatabank version has introduced a mechanism for capturing all the required information for reporting an ADR to the Regulatory Authority. In the UK this consists of submitting a Yellow Card to the MHRA



The industrial version of MiDatabank also has this facility as an alternative to passing the ADR to their Pharmacovigilance department.

The report shown below is an example report that might be submitted by MiDatabank to the MHRA in the UK. The data is electronically sent over the internet and is a direct database to database connection that makes the process quick, easy and efficient.



MiDatabank Sample ADR Report

YellowCard



Helping to make medicines safer

Adverse Drug Reactions **Suspected
In Confidence**

MiDatabank User Name: Sam Smith
User Guid:0e1bdacf-a529-40c0-99cb-7d094cd0e0ce
MI Centre: Demonstration Site

Reporter:

Mr Sam Smith
Manager
Demonstration Site
CoAcS
Avon
Email: dfsf

Title:
Local ID: 220
Global ID: 3395e8d2-0f7d-4911-a600-802fb3f2c192

Adverse Event

Serious: False

Fatal: False
Life Threatening: False
Hospitalisation: False
Significant Disability: False
Congenital Anomaly: False
Other Medical Event: False

Patient Details

Local Patient ID: 3395e8d2-0f7d-4911-a600-802fb3f2c192
Age: 56 Years on 29/01/2010
Sex: Male

Patient Medication

Suspected Drug(s)

Atorvastatin 40mg tablets>Lipitor 40mg tablets

SUSPECT DRUG

Action Taken:Dose reduced

Expiry: 01/01/2012

Batch:

Dose:

Route: Oral

Start Date: 03/12/2009

End Date: <None>

Prescribed For:

Notes:

Concomitant Drug(s)

Aspirin 500mg / Codeine 8mg dispersible tablets sugar free

CONCOMITANT DRUG

Expiry: 01/01/2012

Batch:

Dose:

Start Date: <None>

End Date: <None>

Prescribed For:

Notes:

Adverse Event Details

The patient has reported intense migraine and a sudden rash of septic spots.

Reporter Comments

This is not a real ADR and is shown for demonstration purposes only.

Reactions

Reaction: Septic spots

Outcome: Recovered/Resolved



Start Date: 03/12/2009
End Date: <None>
Treatment: <none specified>

End of Adverse Event

MiDatabank © Copyright 2004 - 2013 CoAcS Ltd